Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute, Suburban
mi
from
Louisville, KY
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute, Suburban
mi
from
Louisville, KY
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Institute
mi
from
Southfield, MI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Institute
mi
from
Southfield, MI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Hackensack University
mi
from
Hackensack, NJ
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Hackensack University
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Hematology-Oncology Associates of Northern Jersey
mi
from
Morristown, NJ
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Hematology-Oncology Associates of Northern Jersey
mi
from
Morristown, NJ
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hospital
mi
from
New York, NY
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
SCRI-Oncology Hematology Care
mi
from
Cincinnati, OH
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
SCRI-Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma
mi
from
Oklahoma City, OK
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Upstate Oncology Associates
mi
from
Greenville, SC
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Upstate Oncology Associates
mi
from
Greenville, SC
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Texas Onocolgy-Baylor Sammons Cancer Center
mi
from
Dallas, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Texas Onocolgy-Baylor Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
UTMB Galveston
mi
from
Galveston, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
UTMB Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Houston Methodist
mi
from
Houston, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Houston Methodist
mi
from
Houston, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
mi
from
Leesburg, VA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Leesburg, VA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer Partnership
mi
from
Everett, WA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology
mi
from
Green Bay, WI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology
mi
from
Green Bay, WI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
City of Hope
mi
from
Duarte, CA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Center
mi
from
Stanford, CA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
St George Hospital
mi
from
Kogarah,
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
St George Hospital
mi
from
Kogarah,
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
SCRI - Florida Cancer Specialists North Region
mi
from
Saint Petersburg, FL
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
SCRI - Florida Cancer Specialists North Region
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine Division of Oncology
mi
from
Saint Louis, MO
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine Division of Oncology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer
Minocycline for Reduction of Symptom Burden After Surgery in Patients With Head and Neck Malignancy: A Randomized Study
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer
Minocycline for Reduction of Symptom Burden After Surgery in Patients With Head and Neck Malignancy: A Randomized Study
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
Micafungin Anti-Fungal Prophylaxis in Immunocompromised Pediatric Patients: A Pharmacokinetic Study
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
Micafungin Anti-Fungal Prophylaxis in Immunocompromised Pediatric Patients: A Pharmacokinetic Study
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center - School of Dental Medicine
mi
from
Farmington, CT
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center - School of Dental Medicine
mi
from
Farmington, CT
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
New York University College of Dentistry
mi
from
New York, NY
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
New York University College of Dentistry
mi
from
New York, NY
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center - Dental Clinic
mi
from
Charlotte, NC
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center - Dental Clinic
mi
from
Charlotte, NC
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania School of Dental Medicine
mi
from
Philadelphia, PA
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania School of Dental Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
The University of North Carolina School of Dentistry
mi
from
Chapel Hill, NC
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
The University of North Carolina School of Dentistry
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials